Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Recent health updates see UnitedHealth shareholders challenging healthcare denial impacts. BRCA2 cancer gene mutation risks ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

Patients with a form of breast cancer in England will be offered a new treatment after it was given the green light for NHS ...

Testing BRCA2 has long been a staple of hereditary cancer testing, as pathogenic variants in the gene are associated with cancers of the breast, ovary, prostate, and pancreas. 2-5 Despite the ...